Skip to main content
    C

    CureVac NV (CVAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.66
    +0.00 (+0.00%)

    Market Cap: $1.05B

    Last updated: Nov 13, 2026 at 4:00 PM ET

    CureVac NV (CVAC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 24, 2025. Financial statements from company filings, amounts in EUR.

    CureVac NV reported revenue of EUR 535.18M for the fiscal year ended Dec 31, 2024, up 895.5% from the year before. That year, net income was EUR 162.19M with a net margin of 30.3%, operating cash flow was EUR 101.85M and free cash flow was EUR 83.41M. The quarter ended Sep 30, 2025 had revenue of EUR 493.90M and net income of EUR 338.04M.

    Revenue and Margins

    The operating margin was 33.2% in the fiscal year ended Dec 2024. Over the 6 years to Dec 2024, revenue grew from EUR 12.87M, a compound annual rate of 86.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024535.18M+895.5%80.2%33.2%30.3%
    Dec 202353.76M-20.3%-131.3%-510.1%-484.0%
    Dec 202267.42M-34.5%-172.9%-370.0%-369.4%
    Dec 2021102.99M+110.6%-131.3%-400.3%-399.8%
    Dec 202048.90M+180.8%71.0%-253.6%-264.0%
    Dec 201917.42M+35.3%-60.7%-571.3%-573.5%
    Dec 201812.87MN/A-37.9%-565.8%-553.5%
    Annual, fiscal years ended Dec 2018 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, net income turned positive after a loss the year before. In the quarter ended Sep 2025, net income was unchanged from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue535.18M53.76M67.42M102.99M48.90M17.42M12.87M
    Cost of revenue105.83M124.37M183.99M238.19M14.17M27.98M17.74M
    Gross profit429.35M-70.61M-116.57M-135.21M34.73M-10.57M-4.87M
    Research and development153.03M115.72M62.55M815.91M113.81M43.24M41.72M
    Operating income177.68M-274.21M-249.46M-412.26M-124.00M-99.50M-72.82M
    Net income162.19M-260.17M-249.03M-411.72M-129.07M-99.87M-71.24M
    EBITDA209.69M-234.09M-209.39M-386.49M-123.09M-93.90M-69.85M
    Fiscal years ended Dec 2018 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue493.90M1.25M893.00K14.47M493.90M14.44M12.37M22.57M16.48M7.58M7.13M11.69M
    Gross profit472.97M-968.00K18.00K12.98M471.97M-26.29M-29.32M-31.03M-7.80M-18.27M-13.51M-68.31M
    Operating income368.38M-61.75M-54.73M-40.99M368.38M-73.62M-73.32M-89.11M-54.04M-71.80M-60.35M-121.51M
    Net income338.04M-59.56M-52.08M-32.76M338.04M-72.54M-70.55M-86.65M-48.68M-67.41M-57.42M-128.78M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of EUR 5.32M by 476.43M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets802.83M788.25M860.47M1.16B1.51B130.62M125.66M
    Current assets526.41M478.38M584.03M940.02M1.39B57.17M73.07M
    Cash and equivalents481.75M402.45M495.80M811.46M1.32B30.68M21.38M
    Total liabilities106.22M271.31M327.22M469.77M800.01M173.42M93.58M
    Short-term debt5.32M5.00M4.98M3.47M3.23M2.00M217.00K
    Long-term debtN/AN/AN/AN/AN/A65.02MN/A
    Shareholder equity696.61M516.94M533.25M688.48M711.35M-42.80M32.08M
    Fiscal years ended Dec 2018 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets1.14B688.88M742.27M802.83M854.19M556.84M690.43M788.25M842.57M899.48M973.67M860.47M
    Total liabilities267.39M102.51M95.58M106.22M129.49M180.30M243.52M271.31M240.30M250.43M260.27M327.22M
    Cash and equivalents416.09M392.70M438.33M481.75M550.86M202.51M300.15M402.45M464.14M537.92M617.52M495.80M
    Shareholder equity871.23M586.37M646.69M696.61M724.70M376.53M446.91M516.94M602.26M649.05M713.40M533.25M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2024, free cash flow was 81.9% of operating cash flow.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow101.85M-267.89M-286.18M-733.13M522.40M-86.96M-74.11M
    Capital expenditures18.44M55.20M93.22M127.90M47.35M12.22M14.72M
    Free cash flow83.41M-323.09M-379.40M-861.03M475.05M-99.19M-88.83M
    Investing cash flow-18.44M-55.20M-93.50M-127.90M-45.27M28.18M-4.26M
    Financing cash flow-5.11M230.89M63.17M344.96M819.83M67.98M-112.00K
    Fiscal years ended Dec 2018 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow29.86M-42.06M-41.37M-66.56M354.08M-89.11M-96.55M-43.60M-60.58M-64.12M-99.59M-49.09M
    Capital expenditures322.00K1.55M511.00K2.57M3.30M7.48M5.09M14.41M13.42M14.21M13.16M20.66M
    Free cash flow29.54M-43.62M-41.88M-69.13M350.78M-96.60M-101.64M-58.01M-74.00M-78.32M-112.75M-69.75M
    Last 12 quarters

    Frequently Asked Questions About CVAC

    What is CureVac NV's annual revenue?

    CureVac NV reported revenue of EUR 535.18M for the fiscal year ended Dec 31, 2024.

    How fast is CureVac NV's revenue growing?

    Revenue was up 895.5% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 73.2%.

    Is CureVac NV profitable?

    Yes. CureVac NV reported net income of EUR 162.19M for the fiscal year ended Dec 31, 2024, with a net margin of 30.3%.

    How much free cash flow does CVAC generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of EUR 101.85M minus capital expenditures of EUR 18.44M produced free cash flow of EUR 83.41M.

    How much debt does CureVac NV have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of EUR 5.32M and cash and equivalents of EUR 481.75M.